---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026747"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:43:18.744235+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics announces FDA clearance of FT522 IND for Phase 1 trial in B-cell lymphoma

## Summary
- FDA allowed IND for FT522, an induced pluripotent stem cell-derived CAR NK-cell product candidate.
- Phase 1 dose-escalating trial will assess FT522 plus CD20-targeted mAb in relapsed/refractory B-cell lymphoma.
- Two regimens: with or without conditioning chemotherapy; starting dose 300M cells per dose in three-dose schedule.
- Regimen A enrollment to begin first; Regimen B will start after DLT clearance at initial dose level.
- Company presented update at 2023 Jefferies Healthcare Conference on June 7, 2023.

## SEC filing metadata
- accession: 0000950170-23-026747
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017023026747/0000950170-23-026747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017023026747/fate-20230607.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026747
- JSON: https://secwatch.observer/filing/0000950170-23-026747.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.